Enliven Therapeutics Inc. (ELVN) - Net Assets
Based on the latest financial reports, Enliven Therapeutics Inc. (ELVN) has net assets worth $453.37 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($464.85 Million) and total liabilities ($11.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Enliven Therapeutics Inc. to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $453.37 Million |
| % of Total Assets | 97.53% |
| Annual Growth Rate | 64.1% |
| 5-Year Change | 329.99% |
| 10-Year Change | N/A |
| Growth Volatility | 165.68 |
Enliven Therapeutics Inc. - Net Assets Trend (2017–2025)
This chart illustrates how Enliven Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. See Enliven Therapeutics Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Enliven Therapeutics Inc. (2017–2025)
The table below shows the annual net assets of Enliven Therapeutics Inc. from 2017 to 2025. For live valuation and market cap data, see Enliven Therapeutics Inc. (ELVN) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $459.49 Million | +48.30% |
| 2024-12-31 | $309.85 Million | +26.00% |
| 2023-12-31 | $245.91 Million | +420.09% |
| 2022-12-31 | $-76.83 Million | -171.89% |
| 2021-12-31 | $106.86 Million | +26.56% |
| 2020-12-31 | $84.44 Million | +192.00% |
| 2019-12-31 | $28.92 Million | +392.35% |
| 2018-12-31 | $5.87 Million | -32.78% |
| 2017-12-31 | $8.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Enliven Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32721300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $59.00K | 0.01% |
| Other Comprehensive Income | $334.00K | 0.07% |
| Other Components | $806.37 Million | 175.45% |
| Total Equity | $459.60 Million | 100.00% |
Enliven Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Enliven Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Meitu Inc
F:M5U
|
$2.46 Billion |
|
Bufab Holding AB
ST:BUFAB
|
$2.46 Billion |
|
Test Research Inc
TW:3030
|
$2.46 Billion |
|
Sichuan Development Lomon Co Ltd
SHE:002312
|
$2.46 Billion |
|
TAV Havalimanlari Holding
IS:TAVHL
|
$2.46 Billion |
|
Arcplus Group PLC
SHG:600629
|
$2.46 Billion |
|
Electra Ltd
TA:ELTR
|
$2.45 Billion |
|
Gansu Shangfeng Cement Co Ltd
SHE:000672
|
$2.45 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enliven Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 309,845,000 to 459,600,000, a change of 149,755,000 (48.3%).
- Net loss of 103,694,000 reduced equity.
- Share repurchases of 620,000 reduced equity.
- New share issuances of 216,169,000 increased equity.
- Other comprehensive income increased equity by 279,000.
- Other factors increased equity by 37,621,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-103.69 Million | -22.56% |
| Share Repurchases | $620.00K | -0.13% |
| Share Issuances | $216.17 Million | +47.03% |
| Other Comprehensive Income | $279.00K | +0.06% |
| Other Changes | $37.62 Million | +8.19% |
| Total Change | $- | 48.33% |
Book Value vs Market Value Analysis
This analysis compares Enliven Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.25x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-3.60 | $42.55 | x |
| 2018-12-31 | $-6.09 | $42.55 | x |
| 2019-12-31 | $-11.31 | $42.55 | x |
| 2020-12-31 | $19.23 | $42.55 | x |
| 2021-12-31 | $13.67 | $42.55 | x |
| 2022-12-31 | $-12.29 | $42.55 | x |
| 2023-12-31 | $6.92 | $42.55 | x |
| 2024-12-31 | $6.58 | $42.55 | x |
| 2025-12-31 | $8.11 | $42.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enliven Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-22.56%) is below the historical average (-15.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.71 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.58 Million |
| 2020 | -22.46% | 0.00% | 0.00x | 1.08x | $-27.41 Million |
| 2021 | -23.15% | 0.00% | 0.00x | 1.06x | $-35.43 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.98 Million |
| 2023 | -29.11% | 0.00% | 0.00x | 1.11x | $-96.17 Million |
| 2024 | -28.73% | 0.00% | 0.00x | 1.05x | $-120.01 Million |
| 2025 | -22.56% | 0.00% | 0.00x | 1.04x | $-149.65 Million |
Industry Comparison
This section compares Enliven Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enliven Therapeutics Inc. (ELVN) | $453.37 Million | 0.00% | 0.03x | $2.46 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more